Equivalence of topical clobetasone and dexamethasone in experimental corneal allograft rejection

KIRK R. WILHELMUS, PAUL A. HUNTER, AND NOEL S. C. RICE
From the Pocklington Eye Transplantation Research Unit, Institute of Ophthalmology, London

SUMMARY We produced experimental immune reactions by exchanging peripheral corneal transplants between rabbits. Clobetasone butyrate 0.1% and dexamethasone phosphate 0.1% eye drops were equally effective in delaying corneal allograft rejection.

Allograft rejection is a leading cause of corneal transplant failure. Studies in rabbits have demonstrated the use of corticosteroids in the prevention of these immune responses. Because a new steroid clobetasone butyrate may have effective anti-inflammatory and immunosuppressive properties, we have compared it with dexamethasone in an experimental model of penetrating keratoplasty.

Material and methods

We performed penetrating keratoplasties on pairs of outbred Dutch pigmented and New Zealand white rabbits weighing 1–2.5 kg. Anaesthesia was induced with intravenous pentobarbitone sodium. Each animal then received amethocaine 1%, cyclopentolate HC1 1%, and phenylephrine HC1 10% topically and 2500 units/kg heparin intravenously. Under operating microscopes peripheral 6 mm corneal buttons were exchanged between pigmented and albino rabbits; the grafts were positioned eccentrically 1–2 mm from the corneoscleral limbus and secured with a continuous 10-0 monofilament nylon suture. Each animal received atropine 1% and chloramphenicol 0.5% eyedrops postoperatively.

Twenty animals were randomly assigned to one of two treatment groups. Group 1 received dexamethasone sodium phosphate 0.1% solution; group 2 received clobetasone butyrate 0.1% suspension (Eumovate). Treatment was begun at the conclusion of surgery and continued 4 times daily for 14 days. Sutures were then removed, and treatment was given twice daily for a subsequent 14 days and then discontinued. Twelve additional animals received only topical atropine and chloramphenicol drops postoperatively as a control group. Only animals in which a successful corneal graft cleared within 2 days were included in the study.

We performed biomicroscopic slit-lamp examinations of each animal at alternate-day intervals. The onset of the allograft reaction was judged to occur when one or more of the following were first noted at the peripheral edge of the graft: an epithelial rejection line (Fig. 1), a whitish band of stromal infiltrate, or a line of keratic precipitates on the endothelium with adjacent stromal oedema.

We compared the treatments by constructing actuarial survival curves to the onset of rejection and used Student’s t test and the logrank test to assess statistical differences.

Correspondence to Mr N. S. C. Rice, Professorial Unit, Moorfields Eye Hospital, City Road, London ECl.

Fig. 1 Epithelial rejection line stained with methylene blue in a peripheral corneal transplant.
Results

Corneal vascularisation occurred in all animals. Vessels first entered the corneal graft after 7.5 ± 1.4 days in the control animals; 7.3 ± 1.7 days in rabbits treated with clobetasone, and 7.6 ± 2.1 days in rabbits treated with dexamethasone (p > 0.5). Two animals receiving dexamethasone died 7 and 22 days post-operatively—one with an upper respiratory tract infection and another with diarrhoea.

Graft rejection occurred in 28 of the 30 surviving animals within 60 days (Fig. 2). All control animals developed a corneal allograft reaction. The onset of graft rejection was delayed in both the clobetasone-treated and dexamethasone-treated animals compared with the control group (p < 0.05). No significant difference was present between the 2 treatment groups (p > 0.3).

Discussion

After keratoplasty afferent recognition of transplanted antigens may take place by conjunctival, intracorneal, or transcameral routes. Corticosteroids such as dexamethasone and prednisolone are useful in suppressing the subsequent allograft reaction by interference with antigen processing and lymphocyte proliferation as well as by their anti-inflammatory and vasoconstrictive properties. However, because adverse effects such as ocular hypertension may occur, steroids with limited intraocular penetration such as fluorometholone have been evaluated in the prevention of immune graft rejection. Clobetasone butyrate is a recently developed steroid which is clinically effective in decreasing ocular inflammation with minimal effect on intraocular pressure. We therefore compared it with dexamethasone in rabbits undergoing corneal transplantation.

Because central penetrating corneal allografts in avascular rabbit corneas are not consistently rejected, the immune reaction produced by an eccentrically placed graft provides a more reliable model for assessing topical immunosuppressive drugs. Vascularisation of the graft occurs at an average of 7.5 days after transplantation and rejection 1 to 3 weeks later. Topical steroids were shown to delay the onset of rejection; clobetasone and dexamethasone were equally effective at the dosage regimen used. The occurrence of an immune reaction after dosage reduction from 4 to 2 times per day suggests that twice-daily use is insufficient to prevent rejection in this experimental model. Prolonged and more frequent applications are necessary to determine if complete inhibition of graft rejection can be achieved.

As a result of improvements in surgical technique and preservation of donor material graft rejection remains the leading cause of late failure of corneal transplants. Extended steroid use may be required to control an immune reaction despite the risk of deleterious side effects. Clobetasone butyrate may offer a useful alternative to dexamethasone following corneal transplantation in patients genetically predisposed to steroid-induced glaucoma.

This study was supported by a grant from the Board of Governors, Moorfields Eye Hospital, and by a fellowship from the Friends of Moorfields Eye Hospital (Dr Wilhelmus). Dr W. Ng provided technical assistance.

References

Equivalence of topical clobetasone and dexamethasone in experimental corneal allograft rejection


